drugset / Trial / NCT00004212

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

NCT00004212

Phase 1 Completed Daiichi Sankyo
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid tumors or lymphomas that have not responded to previous therapy.

Timeline

Start
1999-09
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject exatecan Small molecule Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous